EP0715619A4 - Inhibitors of tnf-alpha secretion - Google Patents

Inhibitors of tnf-alpha secretion

Info

Publication number
EP0715619A4
EP0715619A4 EP94925940A EP94925940A EP0715619A4 EP 0715619 A4 EP0715619 A4 EP 0715619A4 EP 94925940 A EP94925940 A EP 94925940A EP 94925940 A EP94925940 A EP 94925940A EP 0715619 A4 EP0715619 A4 EP 0715619A4
Authority
EP
European Patent Office
Prior art keywords
tnf
inhibitors
alpha secretion
secretion
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94925940A
Other languages
German (de)
French (fr)
Other versions
EP0715619A1 (en
Inventor
Roy A Black
Jeffrey N Fitzner
Paul R Sleath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0715619A1 publication Critical patent/EP0715619A1/en
Publication of EP0715619A4 publication Critical patent/EP0715619A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP94925940A 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion Ceased EP0715619A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US110601 1993-08-23
US18301994A 1994-01-18 1994-01-18
US183019 1994-01-18
PCT/US1994/009343 WO1995006031A1 (en) 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion

Publications (2)

Publication Number Publication Date
EP0715619A1 EP0715619A1 (en) 1996-06-12
EP0715619A4 true EP0715619A4 (en) 1997-03-19

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925940A Ceased EP0715619A4 (en) 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion

Country Status (8)

Country Link
EP (1) EP0715619A4 (en)
JP (1) JPH09503201A (en)
AU (2) AU687436B2 (en)
CA (1) CA2170158A1 (en)
FI (1) FI960803A (en)
NO (1) NO960723L (en)
NZ (1) NZ271893A (en)
WO (1) WO1995006031A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77282A (en) 1994-10-05 1998-03-30 Darwin Discovery Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
CA2217859A1 (en) * 1995-05-10 1996-11-14 David Alan Owen Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US5883241A (en) * 1995-09-05 1999-03-16 Celltech Therapeutics Limited DNA sequences coding for a human metalloproteinase and variants thereof
IL123430A (en) * 1995-10-05 2001-04-30 Darwin Discovery Ltd Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE205184T1 (en) 1995-11-23 2001-09-15 British Biotech Pharm METALLOPROTEINASE INHIBITORS
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
EP0925278B1 (en) 1996-09-10 2002-07-17 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
WO1998057657A1 (en) * 1997-06-18 1998-12-23 The Rockefeller University Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
CA2316296A1 (en) * 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Use of csaidtm compounds for the management of uterine contractions
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
WO2000018358A2 (en) * 1998-09-30 2000-04-06 The Procter & Gamble Company Method of treating hair loss using ketoamides
WO2000018361A2 (en) * 1998-09-30 2000-04-06 The Procter & Gamble Company Method of treating hair loss using sulfonamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
AU2436600A (en) * 1999-01-13 2000-08-01 Jomaa Pharmaka Gmbh Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002028829A2 (en) * 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
CN113194954A (en) 2018-10-04 2021-07-30 国家医疗保健研究所 EGFR inhibitors for the treatment of keratoderma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268933A (en) * 1992-07-23 1994-01-26 British Bio Technology Hydroxysuccinyl hydroxyamines
WO1995013289A1 (en) * 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
WO1995033709A1 (en) * 1994-06-03 1995-12-14 F. Hoffmann-La Roche Ag Hydroxylamine derivatives and their use as metalloproteinase inhibiting agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207097B1 (en) * 1984-12-19 1990-08-08 Ciba-Geigy Ag New carbonic acid esters
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268933A (en) * 1992-07-23 1994-01-26 British Bio Technology Hydroxysuccinyl hydroxyamines
WO1995013289A1 (en) * 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
WO1995033709A1 (en) * 1994-06-03 1995-12-14 F. Hoffmann-La Roche Ag Hydroxylamine derivatives and their use as metalloproteinase inhibiting agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9506031A1 *

Also Published As

Publication number Publication date
JPH09503201A (en) 1997-03-31
FI960803A0 (en) 1996-02-22
EP0715619A1 (en) 1996-06-12
WO1995006031A1 (en) 1995-03-02
AU5030298A (en) 1998-03-05
AU7569494A (en) 1995-03-21
NO960723D0 (en) 1996-02-23
CA2170158A1 (en) 1995-03-02
FI960803A (en) 1996-04-22
NO960723L (en) 1996-02-23
NZ271893A (en) 1997-11-24
AU687436B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
EP0715619A4 (en) Inhibitors of tnf-alpha secretion
PL314838A1 (en) Inhibitors of bp-iv-serine protease
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
AP9701054A0 (en) Inhibitors of cycteine protease
HU9302080D0 (en) Amine-diole protease inhibitors
CY2164B1 (en) Sulfonamide inhibitors of hiv-aspartyl protease
ZA939285B (en) Inhibitors of aspartyl protease
EP0693083A4 (en) Alpha-ketoamide derivatives as inhibitors of thrombosis
EP0814814A4 (en) Methods for the treatment of thrombosis
GB9521265D0 (en) Inhibitors of prenyl-protein transferases
PL328665A1 (en) Inhibitors of serinic protease
AU2251892A (en) Inhibitors of picornavirus proteases
IL126860A0 (en) Inhibitors of the production of s-cd23 and secretion of tnf
GB9315846D0 (en) Tumour inhibitors
PL313740A1 (en) Method of
EP0652897A4 (en) Peptide inhibitors of selectin binding.
GB9109122D0 (en) Treatment of polyurethane surfaces
EP0713496A4 (en) Fibrin-targeted inhibitors of thrombin
GB9311043D0 (en) Inhibitors of nef-cd4 binding
EP0543936A4 (en) Renin inhibitors
GB9321679D0 (en) Treatment of substrates
GB9405905D0 (en) Inhibitors of isoprenylated protein endoprotease
ZA946331B (en) Pyran-4-ylmethyl-substituted arylalkylaryl- arylalkenylylaryl- and arylalkynylarylurea inhibitors of 5-lipoxygenase
ZA924089B (en) Novel thrombin inhibitors
ZA935243B (en) Aminedediol protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980515

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19990823